Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.40)
# 328
Out of 5,154 analysts
241
Total ratings
44.24%
Success rate
26.41%
Average return
Main Sectors:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RNAC Cartesian Therapeutics | Upgrades: Overweight | $16 | $8.50 | +88.24% | 1 | Mar 9, 2026 | |
| QURE uniQure | Upgrades: Neutral | $55 → $9 | $17.36 | -48.16% | 11 | Mar 2, 2026 | |
| IRON Disc Medicine | Maintains: Overweight | $153 → $125 | $63.25 | +97.63% | 10 | Feb 17, 2026 | |
| EPRX Eupraxia Pharmaceuticals | Maintains: Overweight | $11 → $19 | $7.92 | +139.90% | 2 | Jan 15, 2026 | |
| FOLD Amicus Therapeutics | Downgrades: Neutral | $21 → $15 | $14.34 | +1.15% | 8 | Dec 19, 2025 | |
| DBVT DBV Technologies | Maintains: Overweight | $42 → $48 | $23.19 | +107.03% | 2 | Dec 17, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Overweight | $15 → $24 | $7.77 | +209.08% | 5 | Dec 8, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Overweight | $19 | $7.56 | +151.32% | 2 | Dec 1, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Overweight | $29 → $24 | $9.08 | +164.32% | 4 | Nov 6, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $32 → $38 | $28.55 | +33.10% | 9 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $46 → $63 | $53.11 | +18.62% | 4 | Sep 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $105 | $22.68 | +363.07% | 20 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $118 | $66.74 | +76.81% | 21 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $74 | $56.21 | +31.65% | 2 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $16 | $7.83 | +104.34% | 1 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $30.20 | -0.66% | 6 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $163 → $81 | $17.65 | +358.92% | 16 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $4.64 | +50.86% | 16 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $67 → $123 | $40.12 | +206.58% | 6 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $4.15 | +2,068.67% | 4 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $0.40 | +1,650.00% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $15.68 | +59.49% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $30.72 | +118.10% | 15 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $17 | $4.31 | +294.43% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $2.95 | +171.19% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $11 | $1.26 | +773.02% | 6 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $5.22 | +244.83% | 8 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $0.73 | +1,827.58% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $1.21 | +974.38% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.20 | +1,650.00% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.86 | +223.45% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $0.43 | +4,551.16% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $6.66 | +245.35% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $900 | $0.88 | +102,172.73% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $27.91 | +1,333.43% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $2.43 | +3,397.94% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $6.26 | +2,777.70% | 1 | Dec 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $1.87 | +9,525.67% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $1.66 | +562.65% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.48 | +3,954.05% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $0.75 | +11,884.02% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $0.66 | +381,313.65% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $3,040 | $7.14 | +42,477.03% | 1 | Jan 9, 2020 |
Cartesian Therapeutics
Mar 9, 2026
Upgrades: Overweight
Price Target: $16
Current: $8.50
Upside: +88.24%
uniQure
Mar 2, 2026
Upgrades: Neutral
Price Target: $55 → $9
Current: $17.36
Upside: -48.16%
Disc Medicine
Feb 17, 2026
Maintains: Overweight
Price Target: $153 → $125
Current: $63.25
Upside: +97.63%
Eupraxia Pharmaceuticals
Jan 15, 2026
Maintains: Overweight
Price Target: $11 → $19
Current: $7.92
Upside: +139.90%
Amicus Therapeutics
Dec 19, 2025
Downgrades: Neutral
Price Target: $21 → $15
Current: $14.34
Upside: +1.15%
DBV Technologies
Dec 17, 2025
Maintains: Overweight
Price Target: $42 → $48
Current: $23.19
Upside: +107.03%
Fulcrum Therapeutics
Dec 8, 2025
Maintains: Overweight
Price Target: $15 → $24
Current: $7.77
Upside: +209.08%
Lexeo Therapeutics
Dec 1, 2025
Initiates: Overweight
Price Target: $19
Current: $7.56
Upside: +151.32%
Zevra Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $29 → $24
Current: $9.08
Upside: +164.32%
Rigel Pharmaceuticals
Nov 5, 2025
Maintains: Neutral
Price Target: $32 → $38
Current: $28.55
Upside: +33.10%
Sep 30, 2025
Maintains: Overweight
Price Target: $46 → $63
Current: $53.11
Upside: +18.62%
Sep 5, 2025
Reiterates: Overweight
Price Target: $105
Current: $22.68
Upside: +363.07%
Sep 3, 2025
Reiterates: Overweight
Price Target: $118
Current: $66.74
Upside: +76.81%
Aug 27, 2025
Reiterates: Overweight
Price Target: $74
Current: $56.21
Upside: +31.65%
May 22, 2025
Assumes: Overweight
Price Target: $16
Current: $7.83
Upside: +104.34%
May 14, 2025
Reiterates: Overweight
Price Target: $30
Current: $30.20
Upside: -0.66%
May 7, 2025
Maintains: Overweight
Price Target: $163 → $81
Current: $17.65
Upside: +358.92%
Apr 28, 2025
Reiterates: Overweight
Price Target: $7
Current: $4.64
Upside: +50.86%
Mar 27, 2025
Maintains: Overweight
Price Target: $67 → $123
Current: $40.12
Upside: +206.58%
Mar 26, 2025
Reiterates: Overweight
Price Target: $90
Current: $4.15
Upside: +2,068.67%
Mar 18, 2025
Reiterates: Overweight
Price Target: $7
Current: $0.40
Upside: +1,650.00%
Mar 4, 2025
Reiterates: Overweight
Price Target: $25
Current: $15.68
Upside: +59.49%
Jan 29, 2025
Reiterates: Overweight
Price Target: $67
Current: $30.72
Upside: +118.10%
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $4.31
Upside: +294.43%
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $2.95
Upside: +171.19%
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.26
Upside: +773.02%
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.22
Upside: +244.83%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $0.73
Upside: +1,827.58%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $1.21
Upside: +974.38%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.20
Upside: +1,650.00%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.86
Upside: +223.45%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $0.43
Upside: +4,551.16%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $6.66
Upside: +245.35%
Aug 24, 2023
Reiterates: Overweight
Price Target: $900
Current: $0.88
Upside: +102,172.73%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $27.91
Upside: +1,333.43%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $2.43
Upside: +3,397.94%
Dec 29, 2021
Initiates: Overweight
Price Target: $180
Current: $6.26
Upside: +2,777.70%
May 26, 2021
Initiates: Overweight
Price Target: $180
Current: $1.87
Upside: +9,525.67%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $1.66
Upside: +562.65%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $1.48
Upside: +3,954.05%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $0.75
Upside: +11,884.02%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $0.66
Upside: +381,313.65%
Jan 9, 2020
Initiates: Overweight
Price Target: $3,040
Current: $7.14
Upside: +42,477.03%